BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a
biotechnology company focused on immuno-oncology, is currently developing
immunotherapy solutions demonstrated to be highly effective and well tolerated
by patients. The market share for immunotherapy treatments for breast cancer as
well as other malignancies is forecasted to surge in the coming years. An
article discussing the company reads, “Several studies indicate that the
incidence of breast cancer is expected to increase in the next decade (http://ibn.fm/XR9CX). U.S.
breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000
in 2030, an increase of over 50 percent. The proportion of cases diagnosed
among women in the 50–to–69 age group is expected to decrease from 55 percent
to 44 percent in 2030. Diagnoses among those aged 70 to 84, however, will
increase from 24 percent to 35 percent. . . . Immunotherapy could provide a
viable solution to the problem. The cancer immunotherapy market is anticipated
to grow to $145 billion by 2022, at a CAGR of 14 percent (http://ibn.fm/IBQyc).
Immunotherapy currently accounts for 50 percent of the oncology medications
market, but it is forecast that roughly 60 percent of previously treated cancer
patients will adopt immunotherapy by 2026.”
To view the full article, visit http://ibn.fm/hywzI
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized
immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are
personalized to match the patient without the need for personalized
manufacturing. Bria-OTS, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective immune
response against the cancer of each patient while eliminating the time, expense
and complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment